close
close

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual Mechanism Targeting ULBP6 Antibody Currently in Phase 1 Study Page 1

Posted on by Vaseline
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual Mechanism Targeting ULBP6 Antibody Currently in Phase 1 Study Page 1

23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer

Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of adenocarcinomas, providing potential indications to assess clinical activity

Phase 1 trial ongoing, first patient to receive dose in March 2024

Related Posts